Skip Navigation

JNCI Journal of the National Cancer Institute 2001 93(9):661; doi:10.1093/jnci/93.9.661
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 93, No. 9, 661, May 2, 2001
© 2001 Oxford University Press

IN THIS ISSUE

Tamoxifen Beyond 5 Years

The National Surgical Adjuvant Breast and Bowel Project B-14 trial, a large, randomized, placebo-controlled trial of women with estrogen receptor-positive, lymph node-negative breast cancer, demonstrated that 5 years of tamoxifen treatment improves disease-free survival and overall survival. In this issue of the Journal, Fisher et al. (p. 684) present new results from the trial, based on 7 years of follow-up after the initial 5-year treatment period, that address whether tamoxifen treatment for more than 5 years provides additional benefit. The authors found that women who did not continue tamoxifen treatment beyond 5 years had a slight advantage in . . . [Full Text of this Article]

RASSF1A and Lung and Breast Cancers

Trends in Melanoma Incidence

Socioeconomic Status and Prostate Cancer Incidence

p53 Missense Mutations in Ductal Carcinoma In Situ

Alcohol and Breast Cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?